TABLE 1.
Conditions of incubation (°C/min) | Ab or MAb used | % SF-2-infected cells staining, gate 2 | % RF-infected cells staining, gate 2 |
---|---|---|---|
4/30 | None | 1 | <1 |
Seropositive sera | 100 | 100 | |
4117C | 96 | 96 | |
41148D | 80 | 98 | |
37/30 | None | <1 | <1 |
Seropositive sera | 100 | 100 | |
4117C | 93 | 92 | |
41148D | 67 | 86 | |
4/30, then 37/30 | None | <1 | <1 |
Seropositive sera | 100 | 100 | |
4117C | 97 | 97 | |
41148D | 71 | 96 | |
4/30, then 37/60 | None | <1 | <1 |
Seropositive sera | 100 | 100 | |
4117C | 96 | 92 | |
41148D | 72 | 85 | |
4/30, then 37/240 | None | <1 | <1 |
Seropositive sera | 100 | 100 | |
4117C | 97 | 93 | |
41148D | 74 | 88 |
All incubations were done under the conditions given in the table using either no Ab or MAb, pooled seropositive sera at 10−3 dilution, or 4117C or 41148D at 20 μg/ml in a buffer containing 10 mM NaN3 as described previously (1). An aliquot of washed cells from each of these incubations was then counted for viability, while the remainder were reacted with fluorescein isothiocyanate-conjugated goat anti-human IgG at 4°C prior to measurement of fluorescence intensity by flow cytometry as described previously (1). Cell viability after the 4-h incubation at 37°C (final rows of table) was ≥75%, while for all other conditions, it was ≥95%.